clinical trial · NCT05476497
Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects
Peanut AllergyVLP PeanutPlaceboVLP Peanut
brief summary
This phase I clinical trial is designed to evaluate the safety and tolerability of VLP Peanut in healthy subjects and in subjects with peanut allergy (PA). This clinical trial will evaluate the immunotoxicity profile of VLP Peanut in healthy subjects and assess the immunotoxicity profile and the degree of reactogenicity (allergenicity) in subjects with PA. This clinical trial will also explore preliminary proof of efficacy of VLP Peanut in subjects with PA.
started
Oct 17, 2022
primary completion
Nov 1, 2026
completion
Nov 1, 2026
last updated
Mar 13, 2026
official title
A Phase I Clinical Trial to Evaluate the Safety and Tolerability of VLP Peanut in Healthy Subjects and Subjects With Peanut Allergy and to Explore Preliminary Signals of Its Efficacy (PROTECT)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol